These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17211764)

  • 1. [Pharmacoeconomic analyses--chance or 4th hurdle for innovative drugs].
    Krammer H
    Wien Med Wochenschr; 2006 Dec; 156(23-24):606-11. PubMed ID: 17211764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Limitations of pharmacoeconomics from a clinical-pharmacological point of view].
    Müller M
    Wien Med Wochenschr; 2006 Dec; 156(23-24):619-21. PubMed ID: 17211766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Funding innovative medical treatment.
    Holder AR
    Albany Law Rev; 1994; 57(3):795-810. PubMed ID: 11652865
    [No Abstract]   [Full Text] [Related]  

  • 11. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Are drugs worth their cost?].
    Martín-Conde JA; Tévar Alfonso E; García García FJ
    Farm Hosp; 2011 May; 35 Suppl 2():32-9. PubMed ID: 22445507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Medicines Company: an emerging pharmaceutical company in cardiology is spearheading an innovative approach to critical care medicines.
    Mayor S
    Eur Heart J; 2009 Jul; 30(13):1541-3. PubMed ID: 19579293
    [No Abstract]   [Full Text] [Related]  

  • 17. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.